JGC
HRTX icon

J. Goldman & Co’s Heron Therapeutics HRTX Stock Holding History

J. Goldman & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,500
Closed -$629K – 394
2021
Q2 		$629K Buy
+40,500
New +$644K 0.02% 310

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

J. Goldman & Co's HRTX Position: Q4 2025 in Review

J. Goldman & Co sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 67,592 shares — an estimated $85.2K sold.

J. Goldman & Co first reported a position in HRTX in Q2 2015 and held it in 8 quarters. The position peaked at $1.58M in Q3 2022. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • J. Goldman & Co reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 67,592 Heron Therapeutics shares in Q4 2025, an estimated $85.2K.
  • J. Goldman & Co first reported a position in Heron Therapeutics in Q2 2015 and held it in 8 quarters.
  • J. Goldman & Co's Heron Therapeutics position peaked at $1.58M in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.